Chemogenomic profiling of anti-leishmanial efficacy and resistance in the related kinetoplastid parasite Trypanosoma brucei

Collett, CF; Kitson, C; Baker, N; Steele-stallard, HB; Santrot, MV; Hutchinson, S; Horn, D and Alsford, SORCID logo (2019). Chemogenomic profiling of anti-leishmanial efficacy and resistance in the related kinetoplastid parasite Trypanosoma brucei. [Dataset]. European Nucleotide Archive. https://www.ebi.ac.uk/ena/data/view/PRJEB31973
Copy

The arsenal of drugs used to treat leishmaniasis, caused by Leishmania spp., is limited and beset by emergent resistance and toxicity. Our understanding of drug mode-of-action and potential routes to resistance is also limited. Forward genetic approaches have revolutionised our understanding of drug mode-of-action in the related kinetoplastid parasite, Trypanosoma brucei. Therefore, we screened our genome-scale T. brucei RNAi library for knockdowns that render cells resistant to the current anti-leishmanial drugs, sodium stibogluconate (antimonial), paromomycin, miltefosine and amphotericin-B. Identification of T. brucei orthologues of the known Leishmania antimonial and miltefosine plasma membrane transporters effectively validated our approach, while a cohort of 42 novel drug efficacy determinants provides new insights and serves as a resource.

Alternative Title

PRJEB31973

Additional Information

Secondary ID: ERP114591

Keywords

Leishmaniasis

No files available. Please consult associated links.


EndNote BibTeX Reference Manager Refer Atom Dublin Core (with Type as Type) JSON Multiline CSV HTML Citation ASCII Citation OPENAIRE RDF+N3 METS OpenURL ContextObject MODS RDF+N-Triples RDF+XML Data Cite XML MPEG-21 DIDL OpenURL ContextObject in Span EP3 XML Simple Metadata
Export